Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?

To: Jibacoa who wrote (3433)	4/16/2001 3:49:51 PM
From: Biomaven	Read Replies (1) \| Respond to of 52153

I hope we don't get any backtracking on Reg FD: Questions for SEC rule, 6 months later Regulation FD hinders information, critics say cbs.marketwatch.com Personally I think FD has been great for the individual investor that doesn't want to rely on "analysts" to tell him/her what to do. Peter

To: Jibacoa who wrote (3433)	4/16/2001 10:23:48 PM
From: Jibacoa	Respond to of 52153

ABMD: Was up 12.03% BIORY: Was up 23.81% (But only 200 shares traded)<g> RGEN: Was up 10% VLGC: Was up 10.69% In general not bad for a day(specially with present market conditions)<g> VLGC still looks like the best of those four on a "technical basis." siliconinvestor.com siliconinvestor.com Good news on BTGC, the sales of Oxandrin® increased 233% from $5.0 million in the first quarter of 2000 and 69% from $9.9 million in the fourth quarter of 2000 to $16.7 million in the first quarter of 2001.Revenues were up 101% and net income up to $9.5 million vs.$1.1 million: ISELIN, N.J.--(BUSINESS WIRE)--April 16, 2001-- EPS $0.17 Vs. $0.02 (Exclusive of Certain Non-recurring Items) Bio-Technology General Corp. (NASDAQ:BTGC - news) today reported pro forma income from operations of $9.5 million, or $0.17 per share, for the quarter ended March 31, 2001, compared to $1.1 million, or $0.02 per share, in the first quarter of 2000. These results are exclusive of the effect of the write-off, in accordance with generally accepted accounting principles, of purchased in-process technologies resulting from the acquisition of Myelos Corporation on March 19, 2001, and exclusive of the cumulative effect of the change in accounting principle relating to the recognition of contract fee revenues (``SAB 101''), in 2000. Maybe with those good news it will be able to close today's down-gap and climb back to 7.<g>: siliconinvestor.com Bernard